Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Narrative)

v3.21.1
Commitments and Contingencies (Details Narrative)
3 Months Ended 12 Months Ended
Mar. 20, 2021
USD ($)
Jan. 18, 2021
USD ($)
Dec. 21, 2020
USD ($)
Aug. 12, 2020
USD ($)
shares
Aug. 01, 2020
USD ($)
shares
Jul. 15, 2020
USD ($)
shares
Feb. 18, 2020
USD ($)
May 22, 2019
USD ($)
Sep. 12, 2018
USD ($)
Aug. 20, 2018
USD ($)
Apr. 05, 2018
USD ($)
Apr. 05, 2018
EUR (€)
Apr. 02, 2018
Mar. 22, 2018
USD ($)
Sep. 14, 2015
USD ($)
Dec. 24, 2013
USD ($)
Jun. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2019
USD ($)
shares
Research and development costs                                   $ 1,223,676 $ 820,906
Stock options granted to purchase common stock, issued | shares                                   200,000 133,333
Stock options grant date fair value               $ 189,060                   $ 100,000  
NDA Consulting Corp [Member]                                      
Agreement term                               1 year      
Consulting and advisory fee                               $ 4,000   16,000 $ 16,000
Clinical Trial Research Agreement [Member]                                      
Research and development costs                                   102,944  
Clinical Trial Research Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member]                                      
Payments for clinical trial                                   41,142 45,093
Aggregate commitments expected                                   616,000  
Collaboration Agreement [Member]                                      
Research and development costs                                   130,882  
Advance amount related to milestone payment                                 $ 87,471 43,411 87,471
Collaboration Agreement [Member] | Subsequent Event [Member]                                      
Advance amount related to milestone payment $ 23,802                                    
Collaboration Agreement [Member] | Grupo Espanol de Investigacion en Sarcomas [Member]                                      
Advance amount related to milestone payment             $ 43,411                        
Aggregate commitments expected                                   4,614,000  
Collaboration Agreement [Member] | BioPharmaWorks LLC [Member]                                      
Amount charges to operations                                   131,650  
Consulting and advisory fee                             $ 10,000        
Reimbursed expense                                   11,650 100,000
Clinical Trial Agreement [Member]                                      
Aggregate commitments expected                                   $ 5,230,000  
Aggregate commitments expected, description                                   The Company's aggregate commitments pursuant to the aforementioned clinical trial agreements, less amounts previously paid to date under these agreements, totaled approximately $5,230,000 as of December 31, 2020, consisting of approximately $4,614,000 relating to the GEIS clinical trial and approximately $616,000 relating to the Moffit clinical trial, which are expected to be incurred over the next five years through December 31, 2025.  
Clinical Trial Agreement [Member] | City of Hope [Member] | Subsequent Event [Member]                                      
Aggregate commitments expected, description   The Company estimates that from 24 to 30 patients will be needed to complete this clinical trial, at an estimated cost of $2,500,000 to $2,900,000, respectively. If a significant number of patients fail during the dose-escalation process, an increase of up to 12 patients would likely be necessary, at an estimated additional cost of $800,000.                                  
Additional estimated commitments cost   $ 800,000                                  
Clinical Trial Agreement [Member] | City of Hope [Member] | Subsequent Event [Member] | Minimum [Member]                                      
Aggregate commitments expected   2,500,000                                  
Clinical Trial Agreement [Member] | City of Hope [Member] | Subsequent Event [Member] | Maximum [Member]                                      
Aggregate commitments expected   $ 2,900,000                                  
Other Clinical Agreements [Member]                                      
Aggregate commitments expected                                   $ 300,000  
Other Clinical Agreements [Member] | Minimum [Member]                                      
Research and development costs                                   600,000  
Other Clinical Agreements [Member] | Maximum [Member]                                      
Research and development costs                                   700,000  
Work Order Agreement [Member]                                      
Research and development costs                                   75,788  
Aggregate commitments expected                                   874,000  
Work Order Agreement [Member] | Theradex Systems, Inc [Member]                                      
Research and development costs                 $ 954,000                 18,663 51,586
Payment expected dividend for pass-through costs, description                 The clinical trial began in April 2019 and the first patient was entered into the clinical trial in July 2019. At the current rate of accrual, the trial would be completed over a period of four years from its initiation, with the final analysis and reporting expected by July 2023. Costs under this work order agreement are estimated to be approximately $954,000, with such payments expected to be divided approximately 94% to Theradex for services and approximately 6% for payments for pass-through costs.                    
Material Transfer Agreement [Member] | INSERM [Member] | Maximum [Member] | Development Milestones [Member]                                      
Milestone payments                           $ 1,750,000          
Material Transfer Agreement [Member] | INSERM [Member] | Maximum [Member] | Commercial Milestones [Member]                                      
Milestone payments                           $ 6,500,000          
Consulting Agreement with Liberi Life Consultancy BV [Member]                                      
Agreement term                         2 years            
Payment of a fixed, one-time retainer                     $ 18,348                
Net payments of sales of products or licensing activities, percentage                     2.50% 2.50%              
Consulting Agreement with Liberi Life Consultancy BV [Member] | EURO [Member]                                      
Payment of a fixed, one-time retainer | €                       € 15,000              
Consulting Agreement [Member]                                      
Amount charges to operations                                   2,294 9,174
Unamortized balance of the retainer payment                                     9,174
Exclusive License Agreement [Member]                                      
Amount charges to operations                                   $ 25,001 80,669
Royalties description                                   The Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products, subject to reduction to 2% under certain circumstances, on a quarterly basis, with a minimum royalty payment of $50,000 in the first four years after sales commence, and $100,000 in year five and each year thereafter, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in the License Agreement.  
Exclusive License Agreement [Member] | First Four Years [Member]                                      
Minimum payments for royalties                                   $ 50,000  
Exclusive License Agreement [Member] | Five Years and Thereafter [Member]                                      
Minimum payments for royalties                                   100,000  
Exclusive License Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member]                                      
Non-refundable license issue fee                   $ 25,000                  
Annual license maintenance fee                   25,000                  
Payments on non-refundable milestone                   $ 1,897,000                  
Percentage of milestone                   40.00%                  
Employment Agreement [Member] | General and Administrative Expense [Member]                                      
Charges for salary                                   62,500  
Employment Agreement [Member] | Dr. John Kovach [Member]                                      
Annual salary           $ 250,000                       45,000 60,000
Employment Agreement [Member] | Eric Forman [Member]                                      
Annual salary           $ 120,000                          
Stock options granted to purchase common stock, issued | shares           350,000                          
Employment Agreement [Member] | Eric Forman [Member] | General and Administrative Expense [Member]                                      
Charges for salary                                   30,000  
Consulting fee                                   38,000 48,000
Employment Agreement [Member] | Dr. James Miser [Member] | General and Administrative Expense [Member]                                      
Charges for salary                                   62,500  
Employment Agreement [Member] | Dr. James Miser [Member]                                      
Annual salary         $ 150,000                            
Stock options granted to purchase common stock, issued | shares         500,000                            
Stock options grant date fair value         $ 143,163                            
Employment Agreement [Member] | Robert N. Weingarten [Member]                                      
Annual salary       $ 120,000                              
Stock options granted to purchase common stock, issued | shares       350,000                              
Stock options grant date fair value       $ 100,214                              
Employment Agreement [Member] | Robert N. Weingarten [Member] | General and Administrative Expense [Member]                                      
Charges for salary                                   46,451  
Consulting fee                                   $ 79,995 $ 80,380
Master Service Agreement [Member] | Foundation for Angelman Syndrome Therapy [Member]                                      
Percentage of proceeds agree to pay under agreement       5.00%                              
Maximum amount received under agreement       $ 250,000                              
Service Agreement [Member] | IRTH Communications, LLC [Member]                                      
Consulting and advisory fee     $ 7,500                                
Stock options grant date fair value     $ 100,000